Cocrystal Pharma Inc. has released an investor presentation detailing its advancements in developing potent antivirals targeting serious diseases, including influenza, norovirus, and coronavirus. The company utilizes a proprietary drug discovery platform developed with Nobel Prize-winning technology to create broad-spectrum antiviral drugs. Current programs include an oral influenza PB2 inhibitor (CC-42344), progressing in Phase 2a studies, and a dual oral norovirus and coronavirus protease inhibitor (CDI-988), which has completed Phase 1 studies. Cocrystal Pharma is also exploring collaboration opportunities for pandemic preparedness and is led by a seasoned team including Nobel laureates. You can access the full presentation through the link below.